In the present study, we found that trastuzumab-resistant HER2+ GC patients usually presented with SRC histology, initial bone metastasis, poor performance status (ECOG ≥ 2), low HER2 AI in FISH and a loss of PTEN expression at diagnosis. Here, ERBB2 is linked to gastric cancer.